Hashmi Shahrukh K, Srivastava Alok, Rasheed Walid, Adil Salman, Wu Tong, Jagasia Madan, Nassar Amr, Hwang William Y K, Hamidieh Amir Ali, Greinix Hildegard T, Pasquini Marcelo C, Apperley Jane F, Aljurf Mahmoud
Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; Department of Internal Medicine, Mayo Clinic, MN, USA.
Department of Hematology, CMC, Vellore, India.
Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):167-172. doi: 10.1016/j.hemonc.2017.05.017. Epub 2017 Jul 14.
The hematopoietic cell transplant (HCT) activity has grown significantly over the past two decades in both developing and developed countries. Many challenges arise in establishing new HCT programs in developing countries, due to scarcity of resources and manpower in expertise in HCT. While cost issues can potentially hinder establishment of new HCT programs in certain regions, the focus on quality and value should be included in the general vision of leadership before establishing an HCT program. The main challenge in most developing countries is the lack of trained/qualified personnel, enormous start-up costs for a tertiary care center, and quality maintenance. Herein, we discuss the main challenges from a cost and quality perspective which occur at initiation of a new HCT program. We give real world examples of two developing countries that have recently started new HCT programs despite significant financial constraints. We also portray recommendations from the Worldwide Network of Blood and Marrow Transplantation for levels of requirements for a new HCT program. We hope that this review will serve as a general guide for new transplant program leadership with respect to the concerns of balancing high quality with concurrently lowering costs.
在过去二十年里,造血细胞移植(HCT)活动在发展中国家和发达国家均显著增加。由于发展中国家资源稀缺以及缺乏造血细胞移植专业人力,在这些国家建立新的造血细胞移植项目面临诸多挑战。虽然成本问题可能在某些地区阻碍新的造血细胞移植项目的建立,但在建立造血细胞移植项目之前,领导层的总体愿景中应纳入对质量和价值的关注。大多数发展中国家面临的主要挑战是缺乏训练有素/合格的人员、三级护理中心的巨大启动成本以及质量维持。在此,我们从成本和质量角度讨论新的造血细胞移植项目启动时出现的主要挑战。我们给出两个发展中国家的实际例子,这两个国家尽管面临重大资金限制,但最近仍启动了新的造血细胞移植项目。我们还阐述了全球血液和骨髓移植网络对新的造血细胞移植项目要求水平的建议。我们希望这篇综述能为新移植项目领导层在平衡高质量与同时降低成本方面的担忧提供一般性指导。